Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
2012
13.8K+
LTM Revenue $9.3B
LTM EBITDA $4.0B
$72.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zoetis has a last 12-month revenue of $9.3B and a last 12-month EBITDA of $4.0B.
In the most recent fiscal year, Zoetis achieved revenue of $9.3B and an EBITDA of $3.9B.
Zoetis expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Zoetis valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $8.5B | $9.3B | XXX | XXX | XXX |
Gross Profit | $5.6B | $6.0B | XXX | XXX | XXX |
Gross Margin | 66% | 65% | XXX | XXX | XXX |
EBITDA | $3.7B | $3.9B | XXX | XXX | XXX |
EBITDA Margin | 43% | 42% | XXX | XXX | XXX |
Net Profit | $2.1B | $2.3B | XXX | XXX | XXX |
Net Margin | 25% | 25% | XXX | XXX | XXX |
Net Debt | $4.3B | $4.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zoetis's stock price is $151.
Zoetis has current market cap of $67.3B, and EV of $72.0B.
See Zoetis trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$72.0B | $67.3B | XXX | XXX | XXX | XXX | $5.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zoetis has market cap of $67.3B and EV of $72.0B.
Zoetis's trades at 7.8x LTM EV/Revenue multiple, and 18.2x LTM EBITDA.
Analysts estimate Zoetis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zoetis and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $72.0B | XXX | XXX | XXX |
EV/Revenue | 7.8x | XXX | XXX | XXX |
EV/EBITDA | 18.7x | XXX | XXX | XXX |
P/E | 27.1x | XXX | XXX | XXX |
P/E/Growth | 2.7x | XXX | XXX | XXX |
EV/FCF | 31.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZoetis's NTM/LTM revenue growth is 3%
Zoetis's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Zoetis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zoetis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zoetis and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 8% | XXX | XXX | XXX | XXX |
EBITDA Margin | 42% | XXX | XXX | XXX | XXX |
EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 44% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
Opex to Revenue | 34% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Mad Paws | XXX | XXX | XXX | XXX | XXX | XXX |
i-Tail | XXX | XXX | XXX | XXX | XXX | XXX |
Central Garden & Pet | XXX | XXX | XXX | XXX | XXX | XXX |
Dogness | XXX | XXX | XXX | XXX | XXX | XXX |
Freshpet | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zoetis acquired XXX companies to date.
Last acquisition by Zoetis was XXXXXXXX, XXXXX XXXXX XXXXXX . Zoetis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Zoetis founded? | Zoetis was founded in 2012. |
Where is Zoetis headquartered? | Zoetis is headquartered in United States of America. |
How many employees does Zoetis have? | As of today, Zoetis has 13.8K+ employees. |
Who is the CEO of Zoetis? | Zoetis's CEO is Ms. Kristin C. Peck. |
Is Zoetis publicy listed? | Yes, Zoetis is a public company listed on NYS. |
What is the stock symbol of Zoetis? | Zoetis trades under ZTS ticker. |
When did Zoetis go public? | Zoetis went public in 2013. |
Who are competitors of Zoetis? | Similar companies to Zoetis include e.g. Mad Paws, i-Tail, Central Garden & Pet, Dogness. |
What is the current market cap of Zoetis? | Zoetis's current market cap is $67.3B |
What is the current revenue of Zoetis? | Zoetis's last 12-month revenue is $9.3B. |
What is the current EBITDA of Zoetis? | Zoetis's last 12-month EBITDA is $4.0B. |
What is the current EV/Revenue multiple of Zoetis? | Current revenue multiple of Zoetis is 7.8x. |
What is the current EV/EBITDA multiple of Zoetis? | Current EBITDA multiple of Zoetis is 18.2x. |
What is the current revenue growth of Zoetis? | Zoetis revenue growth between 2023 and 2024 was 8%. |
Is Zoetis profitable? | Yes, Zoetis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.